Bitcoin price today: dips below $112k, near 6-wk low despite Fed cut bets
In recent transactions disclosed by Standard Biotools Inc. (NASDAQ:LAB), Sean Mackay, the company’s Senior Vice President and Chief Business Officer, executed stock sales totaling $25,784. These transactions occurred over two consecutive days, May 21 and May 22, 2025. The sales come as the stock trades near its 52-week low of $0.92, having declined nearly 15% in the past week. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value assessment.
On May 21, Mackay sold 12,838 shares of common stock at a weighted average price of $1.03 per share. The following day, he sold an additional 12,536 shares at a weighted average price of $1.002 per share. The sales were conducted to satisfy tax obligations arising from the vesting of restricted stock units granted earlier in the year. InvestingPro data shows the company maintains strong liquidity with a current ratio of 6.12, indicating robust short-term financial health.
Following these transactions, Mackay’s direct ownership of Standard Biotools stock stands at 856,293 shares. The sales prices for the shares ranged from $0.9403 to $1.05 per share. For deeper insights into Standard Biotools’ financial health, valuation metrics, and exclusive ProTips, access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Standard Biotools Inc. reported a net loss for the first quarter of 2025, with earnings per share (EPS) of -$0.07, missing analyst expectations of -$0.06. Revenue also fell short, coming in at $40.8 million compared to the projected $45.6 million. This represents a 10% year-over-year decline, primarily due to a decrease in consumables and services revenue, although instrument revenue increased by 24%. The company has set its full-year revenue guidance for 2025 between $165 million and $175 million. Analysts from firms such as TD Cowen and Jefferies discussed the company’s strategic plans, including its partnership with Illumina (NASDAQ:ILMN), which is expected to drive moderate growth in the coming year. Additionally, Standard Biotools introduced new products and noted strong demand for its Hyperion XDI systems. Despite the challenging quarter, the company improved its net loss by 19% year-over-year and reduced its adjusted cash burn by 33%. The company remains optimistic about achieving adjusted EBITDA positive results by 2026 and is exploring strategic mergers and acquisitions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.